Department of Plastic and Reconstructive Surgery, Frenchay Hospital, Bristol BS16 1LE, United Kingdom.
J Plast Reconstr Aesthet Surg. 2013 Jul;66(7):926-30. doi: 10.1016/j.bjps.2013.03.032. Epub 2013 May 9.
Free tissue transfer for breast reconstruction is widely practiced in the UK and its availability forms part of the NICE guidelines in treating breast cancer. Free flap reconstruction scores highly on patient reported outcome measures for both immediate and delayed procedures. However there are significant resource implications and a concern that the financial burden is not adequately met by the fixed price tariff system (Payment by Results). This study aims to compare the cost of treatment with both local financial estimates and reimbursement.
We conducted a prospective costing analysis for 10 consecutive delayed unilateral DIEP breast reconstructions from August 2011 by a single surgeon in Frenchay Hospital, Bristol. Comparison was made to both the hospital's costing estimates and the Health Resource Group (HRG) tariffs received for 27 similar cases performed by the same surgeon in the 2010-11 financial year.
The mean treatment cost for performing a delayed unilateral DIEP procedure was £7628 (±£754 Standard Deviation). This compared to an estimate from the financial department of £8072±(£1683 SD). These values were not significantly different (p=0.27). The HRG tariff was £8792 (±£423 SD). There was an average net income of £720 per case. Personnel in theatre represented the largest cost area at an average of 73% of total cost.
This study highlights that the costs of this procedure have been estimated accurately by the financial department and that the current HRG code provides adequate reimbursement. The new HRG code for 2012-13, HRG JA14z, provides significantly less reimbursement at £7012 and measures need to be taken to address this. This study has identified that personnel costs are the greatest contributor to overall cost and allowed us to recognise and implement changes to improve efficiency.
游离组织移植乳房重建在英国得到广泛应用,其可及性是 NICE 治疗乳腺癌指南的一部分。游离皮瓣重建在即时和延迟手术的患者报告结局测量中得分很高。然而,这需要大量资源,并且有人担心固定价格计费系统(按效果付费)无法充分满足财务负担。本研究旨在比较使用当地财务估算和报销的治疗成本。
我们对 2011 年 8 月由一名外科医生在布里斯托尔 Frenchay 医院进行的 10 例连续单侧 DIEP 乳房延迟重建进行了前瞻性成本分析。比较了与医院成本估算和 2010-11 财政年度同一外科医生进行的 27 例类似病例的健康资源组(HRG)费率。
单侧 DIEP 延迟手术的平均治疗费用为 7628 英镑(±754 英镑标准差)。这与财务部门的估计值 8072±(1683 英镑 SD)相差不大。这些值没有显著差异(p=0.27)。HRG 费率为 8792 英镑(±423 英镑 SD)。每例平均净收入为 720 英镑。手术室人员占总成本的最大成本区域,平均占 73%。
本研究表明,该程序的成本已被财务部门准确估算,并且现行 HRG 代码提供了充足的报销。2012-13 年的新 HRG 代码 HRG JA14z 提供的报销金额明显减少,为 7012 英镑,需要采取措施加以解决。本研究确定人员成本是总成本的最大贡献者,并使我们能够认识到并实施改变以提高效率。